Rituximab and intravenous immunoglobulin treatment in PM/Scl antibody-associated disease: case-based review
Crossref DOI link: https://doi.org/10.1007/s00296-021-05075-z
Published Online: 2022-01-10
Published Print: 2022-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Srikantharajah, Denesh
Lloyd, Mark E.
Kiely, Patrick D. W. http://orcid.org/0000-0002-8091-2717
Text and Data Mining valid from 2022-01-10
Version of Record valid from 2022-01-10
Article History
Received: 28 October 2021
Accepted: 18 December 2021
First Online: 10 January 2022
Declarations
:
: The authors declare that there is no conflict of interest.